Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
NCT ID: NCT01419691
Last Updated: 2016-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
15 participants
INTERVENTIONAL
2011-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00439231
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296
Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
NCT05920668
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
NCT00800566
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
NCT01515176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 2 Dose
Auranofin 6 mg orally in the morning / 6 mg orally in the evening
auranofin
6 mg twice a day for a total of 12 mg total daily dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
auranofin
6 mg twice a day for a total of 12 mg total daily dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory disease after receiving at least 1 prior therapy for CLL
* At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater
* Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than 2x IULN; serum creatinine less than 1.5x ULN)
Exclusion Criteria
* have not recovered from AEs due to agents administered more than 4 weeks prior
* receiving any other investigational agent
* known second malignancy that limits survival to less than 2 years
* known HIV positive
* uncontrolled intercurrent illness
* pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Leukemia and Lymphoma Society
OTHER
Kansas Bioscience Authority
UNKNOWN
Therapeutics for Rare and Neglected Diseases (TRND)
NIH
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suman Kambhampati, MD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kansas Cancer Center
Westwood, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rousselle B, Massot A, Privat M, Dondaine L, Trommenschlager A, Bouyer F, Bayardon J, Ghiringhelli F, Bettaieb A, Goze C, Paul C, Malacea-Kabbara R, Bodio E. Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to in vivo Investigations. ChemMedChem. 2022 Jun 3;17(11):e202100773. doi: 10.1002/cmdc.202100773. Epub 2022 Mar 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hem-2011-05-01
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
12838
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.